How to enable Javascript

Modeling

All topics

NOVA’s approach to Model Informed Drug Development
Jules Henri Poincaré (French mathematician, 1854-1912) Science is facts; just as houses are made of stone, so is science made of facts; but a pile of stones is not a house,…
- updated 9 mths ago
- 40
- Modeling
Part 1. Introductory remarks
TL; DR Models are just simplified representation of a real world with some constraints, which quickly become obsolete and need to be updated from time to time.…
- updated 9 mths ago
- 42
- 2
- Modeling
Part 2. NOVA’s approach reconciles knowledge with data to predict clinical outcomes
TL; DR The M&S approach in MIDD should be designed and operated for the patient's health (in the form of clinical outcome). The M&S is the mix of the top-down problem solving approach and the…
- updated 9 mths ago
- 25
- Modeling
Part 3. NOVA’s Modeling and Simulation approach
TL; DR Clinical outcome is an ultimate focus of the M&S process. Six-steps process consists of: Problem formulation (project plan), Systemic knowledge review (knowledge model), Computational model,…
- updated 9 mths ago
- 25
- Modeling
Part 4. Responders - the M&S perspective
TL; DR One of the most promising contributions of M&S to R&D is the identification of responders. This aspect approaches the field of personalized medicine.…
- updated 9 mths ago
- 13
- Modeling
Part 5. Examples of Effect Model applications
TL; DR The EM serves to run in silico clinical trials cheaper and faster than in vivo clinical trials. EM can be applied from discovery (target selection) to market access (translating trial…
- updated 9 mths ago
- 13
- Modeling
Part 6. Are M&S outputs real?
TL; DR Once the model is suitably validated, it will predict the therapy’s efficacy. This prediction is based on knowledge that science assumes real, and applied to virtual data,…
- updated 9 mths ago
- 10
- Modeling
Part 7. What can NOVA’s approach be used for?
TL; DR NOVA's approach allows for the model to be progressively updated with new information collected in response to the current question and help to answer a consecutive one.…
- updated 9 mths ago
- 8
- Modeling
Part 8. Expected consequences on R&D and future of MIDD
TL; DR Currently, MIDD ideally remains centred on in vivo clinical trials, which are the ultimate proof. In the future, however, it is plausible that in vivo clinical trials will move to the role of…
- updated 9 mths ago
- 11
- Modeling
Part 9. Conclusions
Baruch Spinoza wrote “demonstrations are the eyes of the mind"[1]. By demonstration he meant something like “rigorous reasoning”. If we add “validated”,…
- 10 mths ago
- 13
- Modeling

Welcome to the community!

Modeling

NOVA’s approach to Model Informed Drug Development

Part 1. Introductory remarks

Part 2. NOVA’s approach reconciles knowledge with data to predict clinical outcomes

Part 3. NOVA’s Modeling and Simulation approach

Part 4. Responders - the M&S perspective

Part 5. Examples of Effect Model applications

Part 6. Are M&S outputs real?

Part 7. What can NOVA’s approach be used for?

Part 8. Expected consequences on R&D and future of MIDD

Part 9. Conclusions

Try jinkō!

Categories

Top contributors

Recent activity

Home

Try jinkō!